CRISPR Therapeutics AG Common Shares (CRSP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on CRISPR Therapeutics AG Common Shares (CRSP) is Neutral.

The composite score behind that read is -0.06, weighing +0.40 of bullish evidence against -0.33 bearish.

CRISPR Therapeutics AG Common Shares last closed at $53.39, +5.85% on the session.

Against the IVW growth benchmark the position is +5.05% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for CRSP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks CRISPR Therapeutics AG Common Shares in the 25th percentile on return on equity, where 100 is best.

CRISPR Therapeutics AG Common Shares is classified under Health Care / Biotechnology, with a market capitalisation of $4.88B.

StockMap tracks CRISPR Therapeutics AG Common Shares as the 54th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite CRISPR Therapeutics AG Common Shares ranks 152nd of 381 in the group, against a group median of -0.08.